Perry Creek Capital LP Cybin Inc. Transaction History

Perry Creek Capital LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.41 - $0.88 $482,570 - $1.04 Million	-1,177,000 Reduced 76.75%	356,541 $199,000
Q1 2022 May 16, 2022	SELL	$0.74 - $1.22 $944,326 - $1.56 Million	-1,276,117 Reduced 45.42%	1,533,541 $1.25 Million
Q4 2021 Feb 14, 2022	SELL	$1.13 - $2.31 $54,928 - $112,286	-48,609 Reduced 1.7%	2,809,658 $3.34 Million
Q3 2021 Nov 15, 2021	BUY	$1.83 - $3.18 $5.23 Million - $9.09 Million	2,858,267 New	2,858,267 $6.27 Million

109

243M

Ticker CYBN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 166,120,000
Market Cap $43.2M
Description
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to t...

Get notified when there are updates to the investment portfolio of Perry Creek Capital LP, based on Form 13F filings with the SEC.

Stay updated on Perry Creek Capital LP with notifications on news.